5-氨基水杨酸在结肠和直肠的吸收。
Absorption of 5-aminosalicylic acid from colon and rectum.
作者信息
Bondesen S, Schou J B, Pedersen V, Rafiolsadat Z, Hansen S H, Hvidberg E F
机构信息
Department of Internal Medicine, Elsinore Hospital, Denmark.
出版信息
Br J Clin Pharmacol. 1988 Feb;25(2):269-72. doi: 10.1111/j.1365-2125.1988.tb03301.x.
Abstract
In order to clarify the characteristics of absorption of 5-aminosalicylic acid (5-ASA) from the colon, a neutral solution was instilled into the right part of the colon and the rectum, respectively, in six volunteers. A laxative (bisacodyl) and liquid meals were given prior to each instillation. No significant difference could be demonstrated between the two parts of the large bowel, but the absorption was considerably restricted compared with previous results obtained from the jejunum. The results confirm in a direct manner earlier observations on 5-ASA released from sulphasalazine.
摘要
为了阐明5-氨基水杨酸（5-ASA）在结肠的吸收特性，分别向6名志愿者的结肠右侧和直肠内注入中性溶液。每次注入前均给予泻药（比沙可啶）和流食。大肠的这两个部位之间未显示出显著差异，但与先前从空肠获得的结果相比，吸收受到了相当大的限制。这些结果直接证实了早期对柳氮磺胺吡啶释放的5-ASA的观察结果。
相似文献
1
Absorption of 5-aminosalicylic acid from colon and rectum.5-氨基水杨酸在结肠和直肠的吸收。
Br J Clin Pharmacol. 1988 Feb;25(2):269-72. doi: 10.1111/j.1365-2125.1988.tb03301.x.
2
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.柳氮磺胺吡啶、其代谢产物及其他5-氨基水杨酸前体药物的临床药代动力学。
Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001.
3
Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid.作为5-氨基水杨酸潜在的结肠特异性前药的葡聚糖-5-氨基水杨酸酯的合成与性质
Arch Pharm Res. 1998 Apr;21(2):179-86. doi: 10.1007/BF02974025.
4
Distal ileum and colon: targeted sites for 5-ASA release.回肠末端和结肠：5-氨基水杨酸释放的靶向部位。
Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:300-3.
5
Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.柳氮磺胺吡啶作为5-氨基水杨酸新型结肠靶向前药的生物药学评价
J Drug Target. 1994;2(2):123-31. doi: 10.3109/10611869409015900.
6
Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.评估5-氨基水杨基牛磺酸作为5-氨基水杨酸的结肠特异性前药用于治疗实验性结肠炎的效果。
Eur J Pharm Sci. 2006 May;28(1-2):26-33. doi: 10.1016/j.ejps.2005.12.005. Epub 2006 Feb 7.
7
Synthesis and properties of N,N'-bis(5-aminosalicyl)-L-cystine as a colon-specific deliverer of 5-aminosalicylic acid and cystine.
Drug Deliv. 2008 Jan;15(1):37-42. doi: 10.1080/10717540701828806.
8
Oroileal transit of slow release 5-aminosalicylic acid.缓释5-氨基水杨酸的口腔至回肠转运
Gut. 1993 May;34(5):669-75. doi: 10.1136/gut.34.5.669.
9
Kinetics of 5-aminosalicylic acid after jejunal instillation in man.人空肠滴注5-氨基水杨酸后的动力学
Br J Clin Pharmacol. 1983 Dec;16(6):738-40. doi: 10.1111/j.1365-2125.1983.tb02254.x.
10
Prandial and diurnal effects on the absorption of orally administered enteric coated 5-aminosalicylic acid (5-ASA).进餐和昼夜节律对口服肠溶5-氨基水杨酸（5-ASA）吸收的影响。
Br J Clin Pharmacol. 1992 Feb;33(2):179-82. doi: 10.1111/j.1365-2125.1992.tb04021.x.
引用本文的文献
1
Pharmacokinetic and safety profiles of mesalazine enema in healthy Chinese subjects: A single- and multiple-dose study.在健康中国受试者中，美沙拉嗪灌肠剂的药代动力学和安全性特征：一项单次和多次给药研究。
PLoS One. 2024 Feb 2;19(2):e0296940. doi: 10.1371/journal.pone.0296940. eCollection 2024.
2
Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity.5-[(4-羧基丁酰基)氨基]-2-羟基苯甲酸在Wistar大鼠体内的药代动力学：一种5-氨基水杨酸（5-ASA）的新型合成衍生物，具有潜在的抗炎活性。
PLoS One. 2016 Jul 25;11(7):e0159889. doi: 10.1371/journal.pone.0159889. eCollection 2016.
3
Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults.对健康成年人口服给药后药物所接触的升结肠内容物的特征分析。
Pharm Res. 2009 Sep;26(9):2141-51. doi: 10.1007/s11095-009-9927-x. Epub 2009 Jul 2.
4
Clinical pharmacokinetics of slow release mesalazine.缓释美沙拉嗪的临床药代动力学
Clin Pharmacokinet. 2000 Aug;39(2):85-97. doi: 10.2165/00003088-200039020-00001.
5
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.静脉注射、口服、缓释口服及直肠泡沫给药后硫唑嘌呤的药代动力学。
Gut. 1996 Jul;39(1):63-8. doi: 10.1136/gut.39.1.63.
6
Oroileal transit of slow release 5-aminosalicylic acid.缓释5-氨基水杨酸的口腔至回肠转运
Gut. 1993 May;34(5):669-75. doi: 10.1136/gut.34.5.669.
7
Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.美沙拉嗪。对其药效学和药代动力学特性以及在慢性炎症性肠病中的治疗潜力的综述。
Drugs. 1989 Oct;38(4):500-23. doi: 10.2165/00003495-198938040-00003.
8
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).用于治疗胃肠道疾病的药物的临床药代动力学（第二部分）。
Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002.
9
Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.直肠给药的药代动力学，第二部分。外周作用药物的临床应用及结论。
Clin Pharmacokinet. 1991 Aug;21(2):110-28. doi: 10.2165/00003088-199121020-00003.
10
Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus and per os slow-release formulation.静脉推注和口服缓释制剂给药后人体中5-氨基水杨酸的药代动力学
Dig Dis Sci. 1991 Dec;36(12):1735-40. doi: 10.1007/BF01296618.
本文引用的文献
1
Kinetics of 5-aminosalicylic acid after jejunal instillation in man.人空肠滴注5-氨基水杨酸后的动力学
Br J Clin Pharmacol. 1983 Dec;16(6):738-40. doi: 10.1111/j.1365-2125.1983.tb02254.x.
2
5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern.5-氨基水杨酸灌肠剂用于活动性溃疡性结肠炎患者。酸度对动力学模式的影响。
Scand J Gastroenterol. 1984 Jul;19(5):677-82.
3
Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silica.通过动态改性硅胶上的高效液相色谱法测定生物流体中的5-氨基水杨酸及其乙酰化代谢物。
J Chromatogr. 1981 Dec 11;226(2):504-9. doi: 10.1016/s0378-4347(00)86089-2.
4
Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.大剂量5-氨基水杨酸灌肠剂治疗溃疡性结肠炎
Lancet. 1981 Aug 8;2(8241):270-1. doi: 10.1016/s0140-6736(81)90523-7.
5
Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.柳氮磺胺吡啶及其代谢产物的循环水平及其与该药物在溃疡性结肠炎中临床疗效的关系。
Gut. 1980 Aug;21(8):706-10. doi: 10.1136/gut.21.8.706.
6
7
Absorption, metabolism, and excretion of salicylazosulfapyridine in man.柳氮磺胺吡啶在人体中的吸收、代谢及排泄
Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539-51. doi: 10.1002/cpt1972134539.
8
Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Scand J Gastroenterol. 1986 Aug;21(6):693-700. doi: 10.3109/00365528609011102.
9
Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.
Gastroenterology. 1985 Mar;88(3):717-22. doi: 10.1016/0016-5085(85)90142-8.
10
An experiment to determine the active therapeutic moiety of sulphasalazine.一项确定柳氮磺胺吡啶活性治疗部分的实验。
Lancet. 1977 Oct 29;2(8044):892-5. doi: 10.1016/s0140-6736(77)90831-5.
Zotero 插件